Viridian Therapeutics, Inc.\DE (VRDN) Return on Capital Employed (2014 - 2026)

Viridian Therapeutics, Inc.\DE's Return on Capital Employed history runs 13 years deep, the most recent figure standing at 48.67% for Q1 2026.

• On a quarterly basis, Return on Capital Employed rose 178.0% year-over-year to 48.67% in Q1 2026; TTM through Mar 2026 was 48.67%, a 178.0% increase from a year earlier, with the FY2025 full-year figure at 48.44%, up 416.0% from the prior year.
• Return on Capital Employed rose to 48.67% in Q1 2026 per VRDN's latest filing, from 54.43% in the prior quarter.
• Across five years, Return on Capital Employed topped out at 33.2% in Q4 2022 and bottomed at 73.23% in Q3 2023.
• The 5-year median for Return on Capital Employed is 48.67% (2026), against an average of 52.42%.
• Across the five-year window, Return on Capital Employed surged 6419 bps in 2022 and slumped 3324 bps in 2023, its largest moves.
• Year by year, Return on Capital Employed stood at 33.2% in 2022, then tumbled by 100 bps to 66.44% in 2023, then surged by 37 bps to 42.16% in 2024, then dropped by 29 bps to 54.43% in 2025, then rose by 11 bps to 48.67% in 2026.
• Per Business Quant, the three latest VRDN Return on Capital Employed figures stand at 48.67% (Q1 2026), 54.43% (Q4 2025), and 62.02% (Q3 2025).